Bijal D. Shah, MD, on CAR T-cell therapy and mantle cell lymphoma
Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.
Bijal D. Shah, MD, of the Moffit Cancer Center, discussed the encouraging signs in the early stages of data collection regarding CAR T-cell therapy and mantle cell lymphoma at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida from December 7-10.
Transcription:
Wow I can’t tell you how excited I am about the CAR T data and mantle cell lymphoma. This was a highly refractory population, meaning they had seen BTK now progressing. In our own series of patients, that group of patients had a median survival of somewhere around 2 to 4 months.
High overall response rates, durable remissions at a year, and without any mortality attributed to the CAR T-cell therapy. This is a big deal. For patients with proliferative mantle cell lymphoma, for patients with p53 variant mantle cell lymphoma we desperately need active therapies. And its early, we’ve only seen the first data cut for the abstract, but this preliminary signal of activity is so encouraging. To answer your question ‘is it practice changing,’ absolutely. I can’t imagine that Kite Gilead is not knocking on the FDA’s door right now.
![According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fe0d29c38bb732429ae370e4ef7d1829a10c96446-2992x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”")
